Gunn: 40M reads/sample; showed 100% sens/spec for 1.5%, 0.5%, for both products. For 0.25%, 95-100% sens/spec. Also… https://t.co/nrRcls59mB
2:18pm November 15th 2017 via Hootsuite
Gunn: Product 1: targeted kit; Product 2: expanded kit. Both have 17 key genes in targeted kit; expanded an add'l 60 genes #AMP2017
2:14pm November 15th 2017 via Hootsuite
Gunn: Input is 4mL plasma; FRUO; CNV, SNV, indels and fusions; software and report with secondary analysis as an automated report #AMP2017
Gunn: In-house development, bioinformatics, purchase existing kit, all possible. With Roche: Early-access across 3… https://t.co/oPFhWWdJbh
2:13pm November 15th 2017 via Hootsuite
Gunn: ResearchDx is a CDX-development lab. A 'Contract Dx Organization' in Irvine CA: who was faced with the request in '16 #AMP2017
2:10pm November 15th 2017 via Hootsuite
Gunn: Hard to gauge demand, given phlebotomy oncology samples going straight to testing labs #AMP2017
2:09pm November 15th 2017 via Hootsuite
Gunn: LB promise less invasiveness, lower cost, longitundinal monitoring, better outcomes. Seeing sporadic adoption across the US. #AMP2017
2:08pm November 15th 2017 via Hootsuite
Gunn: FFPE was 'never intended for long-term storage of nucleic acids'. Tissue biopsy disadvantages: invasive, adve… https://t.co/kIH9s4KB9T
Gunn: From a pathologist's perspective: they are trying to adapt. Clear advantages: improved TAT, preservation of F… https://t.co/TztSuCKxPj
2:05pm November 15th 2017 via Hootsuite
Gunn:Introduction of this kit 'has enabled us to enter the liquid biopsy era'. Intorduction to the kit - multiple tumor types. #AMP2017
2:04pm November 15th 2017 via Hootsuite
Roche Workshop: Shelly Gunn (ResearchDx/PacificDx) A lab's perspective: evaluating the new AVENIO ctDNA analysis kits #AMP2017
2:02pm November 15th 2017 via Hootsuite
Longshore: Combine both tissue and plasma samples on the same plate. Commentary on NGS: cumbersome, seems overkill… https://t.co/zzUQGul6Jn
12:35pm November 15th 2017 via Hootsuite
Longshore: Points out how quick real-time cobas 480 results are compared to a 50-gene NGS one; also high sample fai… https://t.co/ol8cHxdFNX
12:25pm November 15th 2017 via Hootsuite
Longshore: but 50-gene NGS seems 'quite a waste' for KRAS, NRAS and BRAF. Utility of cobas z 480: many have them on… https://t.co/YXcQWu6g1r
12:23pm November 15th 2017 via Hootsuite
Longshore: KRAS 12, 13 and 61: 12%. Expanded RAS: 17% of add'l pts. 61, 117, 148. NRAS mutations, and BRAF another… https://t.co/EwBUKTLBnc
12:21pm November 15th 2017 via Hootsuite
Longshore: Many CDx collaborations. Shows a photo of a KRAS codon 12,13 and 61 giant stack of paperwork. "A robust amount of work." #AMP2017
John Longshore (Carolinas Pathology Group) start with their Healtcare system - very large for the Carolinas, base… https://t.co/HipNNI03eZ
12:19pm November 15th 2017 via Hootsuite
Roche: Showed MiSeq comparative method, good concordance; and full-process experiments. Can use 'Semi Quantative In… https://t.co/ugU9jW7EBf
12:14pm November 15th 2017 via Hootsuite
Roche: For BRAF/NRAS in plasma: spiking expt. 7 BRAF / 9 NRAS down to 0.03%; others at 0.13%,. 5 at higher MAF #AMP2017
12:12pm November 15th 2017 via Hootsuite
Roche: 1 at 5% AF, 4 at 2.5% MAF, 31 at 1% MAF from plasma. Using FFPE showed 100% at 5%, all but two at 2.5% MAF done in duplicate #AMP2017
12:11pm November 15th 2017 via Hootsuite
Roche: KRAS v2: 28 mutations in exons 2/3/4; also includes codon 61, 145, 49, 117. Total of BRAF/NRAS and KRAS is 6… https://t.co/finX4T1DpO
12:08pm November 15th 2017 via Hootsuite
Roche: 11 BRAF, 25 NRAS; several exon 11 mutations, also K601E for exploratory purposes. For NRAS, Exon 4 and 3 as well. #AMP2017
12:06pm November 15th 2017 via Hootsuite
Roche: Expanding the Scientific Body of Knowledge with the New BRAF/NRAS Mutation Test and KRAS MutationTest v2 for… https://t.co/3g8iUvwqPS
12:05pm November 15th 2017 via Hootsuite
Q: Specific recommendations for pre-analytical handling? Promega: Have used both EDTA and Streck, recommend double spins. #AMP2017
11:37am November 15th 2017 via Hootsuite
Promega: Developed a concentration cartridge for 1mL binding events to process up to 4mL plasma. 1mL spread across… https://t.co/bn1B4mo8FW
11:27am November 15th 2017 via Hootsuite
Promega: Have Maxwell RSC DNA FFPE and RNA FFPE kits; xylene-free protocol; manual or automated; <1h extraction time #AMP2017
11:18am November 15th 2017 via Hootsuite
Promega: Offers portal software to track samples across modules, network accessible, unified reporting. #AMP2017
11:15am November 15th 2017 via Hootsuite
Promega: Now has Maxprep liquid handler for preprocessing: ProK, lysis; incubate, plunger placement and elution. Tr… https://t.co/dcHqaSbRJh
11:11am November 15th 2017 via Hootsuite
Promega: "Modular Automation Workflows for Maxwell® Nucleic Acid Extraction of Molecular Oncology Sample Types Such… https://t.co/ybgwLufL1m
11:10am November 15th 2017 via Hootsuite
Promega: Maxwell RSC 48 now equipped with a camera. Checking what's on the table vs. what you've said is there. 2x… https://t.co/jCkGIMVUOJ
11:08am November 15th 2017 via Hootsuite
RT @Tecan_Talk: Visiting #SLC for #AMP2017? Don't forget to take a selfie with the ‘You Are Here’ art installation… https://t.co/e42SUmp7iP
10:55am November 15th 2017 via Hootsuite
Q: Is the Oncomine Dx now available? Duncan: Yes, since Sept. Q: Concern about false positives? Ma: Strict cut-off:… https://t.co/TIbc9EUwR0
10:49am November 15th 2017 via Hootsuite
Ma: "This is not the future, this is now." Further increase in sens. would be through error-correction algorithms;… https://t.co/q2irU49tc1
10:40am November 15th 2017 via Hootsuite
Ma: Found a T790M EGFR resistance mutation, from two separate aliquots. Same mutation showed up from separate sampl… https://t.co/RR2nBx4XDT
10:38am November 15th 2017 via Hootsuite
Ma: Have found all mutations found in tumor tissue biopsy (EGFR, KRAS, PIK3CA etc) Goes through one case: Stg IV, P… https://t.co/WFlVjc5qom
10:37am November 15th 2017 via Hootsuite
Ma: 'In our case, a false-positive is definitely a no-no.' Shows a chart of genes, alleles, and allele frequencies… https://t.co/15R5V9QK82
10:36am November 15th 2017 via Hootsuite
Ma: Sens 85%, Spec 99%, down to 0.1%. Sens achieved via barcoding. Allows distinguishing error from true mutation #AMP2017
10:33am November 15th 2017 via Hootsuite
Ma: Challenges: Pt frailty - 17% of biopsies resulted in complications; insufficient material (5% of EGFR single-ge… https://t.co/GBFVDXqw86
10:32am November 15th 2017 via Hootsuite
Ma:Stats around lung ca: 80-85% NSCLC, 15-20% SCLC. EGFR, BRAF, ALK/ROS1 fusion, MET amp all offer specific treatment options #AMP2017
10:31am November 15th 2017 via Hootsuite
Ma: A needle in a haystack, 'but the needle looks different'. Shows sensitivity chart - Sanger at 10-20%, Pyro 5-10… https://t.co/7TWGoBAnTv
10:30am November 15th 2017 via Hootsuite
Ma: cfDNA released from both healthy and tumor cells; apoptosis, necrosis and secretion. Unstable: 20-30ng per 5mL,… https://t.co/iCpAvbWexT
10:29am November 15th 2017 via Hootsuite
Ma: Tumors shed intact cells (CTCs), cellular components (cfDNA and cfRNA) and also exosomes, cell-membrane derived vesicles #AMP2017
10:27am November 15th 2017 via Hootsuite
Ma: Also biospy tissue limited: greater demand due to molecular profiling, surgery is costly (about $37K cost) #AMP2017
Ma:Points out that biopsy is invasive - patient may be in poor condition, or tumor inaccessible; impractical for pr… https://t.co/YefYHB7Ks9
10:25am November 15th 2017 via Hootsuite
Ma: Defines liquid biopsy, with figure from Diaz et al ASCO 32:579 (2014). Advantages: real-time eval and monitorin… https://t.co/9iuiwwiWrQ
Charles Ma (Cancer Genetics Inc) Thermo workshop: "Cell-free DNA and lung cancer clinical research" #AMP2017
10:23am November 15th 2017 via Hootsuite
Thermo: conlcude 'NGS can simplify elaborate testing algorithms and consolidate workflow.' Speaker: Daniel Duncan,… https://t.co/P2SaoitCl3
Thermo: Graphed number of slides consumed per single-gene test (as many as 18 slides for 7 genes) vs 1 for Oncomine… https://t.co/lDEJFJNvSP
10:21am November 15th 2017 via Hootsuite
Thermo: Retrospective analysis at IASLC world conf in lung ca: shows distribution that Core Needle Biopsy (n=1,029)… https://t.co/ZJfCJVyTuG
10:18am November 15th 2017 via Hootsuite
Thermo: Shows NCCN guidelines - BRAF V600E, ROS1, EGFR exon 19 del and Exon 21 L858R. Add'l targets listed, points… https://t.co/59uBLZKYfx
10:16am November 15th 2017 via Hootsuite
